The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 360:1045-1047 March 5, 2009 Number 10
NextNext

Rituximab and Omalizumab in Severe, Refractory Insulin Allergy

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
To the Editor: We describe the sequential use of two targeted biologic agents to treat a patient with severe systemic insulin allergy accompanied by marked metabolic dysregulation and corticosteroid toxicity.

In 1996, a 50-year-old woman received the diagnosis of type 1 diabetes. Shortly after insulin therapy was initiated, a generalized urticarial rash (resulting in excoriation, bleeding, and disrupted sleep) developed. Insulin allergy was diagnosed on the basis of positive skin-prick tests and a level of insulin-specific IgE of 5.75 kU per liter (normal value, <0.70 kU per liter). Until 2000, she was treated with a standard stepwise approach of trying . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.